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Abstract 
Mitochondria isolated from maize containing cms-T cytoplasm are specifically sensitive to pathotoxins (T-toxins) produced by the 
fungi Bipolaris maydis race T and Phyllosticta maydis. T-toxins interact with a 13 kDa membrane-bound toxin receptor protein, URF13, 
to produce hydrophillic pores in the membrane. Expression of URF13 in Escherichia coli produces bacterial cells that form hydrophillic 
pores in the plasma membrane when exposed to T-toxin or methomyl. Topological studies have established that URF13 contains three 
membrane-spanning a-helices, two of which are amphipathic and may contribute to pore formation. URFI 3 specifically binds T-toxin in 
a cooperative manner. Oligonucleotide-directed mutagenesis ofURF13 led to the isolation of methomyl/T-toxin-resistant mutations at 39 
separate positions throughout the URF13 primary sequence. Chemical cross-linking of URFI3 demonstrated the presence of URF13 
oligomers and established that the pore-forming species is oligomeric. The ability of the carboxylate-specific reagent, dicyclohexycarbodi- 
imide to cross-link URF13 has been used in conjunction with site-directed mutagenesis to establish that the URFI 3 tetramer has a central 
core consisting of a four-a-helical bundle that may undergo a conformational change after T-toxin or methomyl binding. Experimental 
evidence indicates that URFI 3 acts as a ligand-gated, pore-forming T-toxin receptor. 
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I. Introduction 
Cytoplasmic male sterility (cms) is a maternally inher- 
ited trait that leads to the formation of non-viable pollen 
during microsporogenesis [1]. Three cms types (T, C and 
S) can be distinguished in maize based upon their interac- 
tion with different nuclear genes that are able to restore 
fertility [1]. Maize carrying cms-T cytoplasm, in 
widespread use in the US in the late 1960s for the produc- 
tion of hybrid seed, is uniquely susceptible to infection by 
the fungus Bipolaris maydis, race T (formerly 
Helminthosporium aydis), leading to a disease known as 
Southern corn leaf blight [2-4]. A second fungus, Phyl- 
losticta maydis, produces the disease, yellow leaf blight, 
on cms-T maize. These fungi each produce a set of 
structurally related pathotoxins, referred to collectively as 
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T-toxins [5], that specifically affect cms-T maize mito- 
chondria, but not mitochondria isolated from normal 
(fertile) maize or any of the other maize cms types [2,6]. 
The effects of T-toxins on isolated cms-T mitochondria 
include the inhibition of malate-supported state 3 respira- 
tion, stimulation of state 4 respiration using succinate or 
external NADH as electron donors, induction of mitochon- 
drial swelling and leakage of small molecules such as 
Ca 2÷ and NAD ÷ [6-10]. These results have led to the 
view that T-toxins produce their toxic effect by permeabi- 
lizing the inner mitochondrial membrane [2,8]. Methomyl 
(S-methyl-N-[(methylcarbamoyl)oxy]thioacetimidate), a 
commercial insecticide that bears no obvious structural 
resemblance to T-toxin, mimics all the observed effects of 
T-toxin on cms-T mitochondria but at 10 4 -  to 105-fold 
higher concentrations [7,8]. 
Forde and Leaver [11] initially demonstrated that a 
unique 13 kDa polypeptide was synthesized by isolated 
cms-T mitochondria. Subsequently, Dewey et al. [12] char- 
acterized a gene specific to the mitochondrial genome of 
cms-T maize (T-urfl3) that encodes a 13 kDa protein, 
URF13. An antibody specific for a 15-amino acid se- 
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quence in the carboxy terminus of URF13 was used to 
show that URF13 is present in cms-T mitochondria and is 
located in the inner mitochondrial membrane [13]. 
Although sensitivity to T-toxin and cytoplasmic male 
sterility in cms-T maize are both correlated with the 
presence of URF13 [14-17], definitive proof of the rela- 
tionship between sensitivity to T-toxin and the URF13 
protein was provided experimentally b  the expression of 
URF13 in Escherichia coil [18]. The resulting bacteria 
were sensitive to T-toxin (or methomyl) as evidenced by 
the inhibition of cellular respiration [18], the immediate 
loss of accumulated 86Rb from the cells [19] and subse- 
quent cell death. The response of E. coli cells expressing 
URF13 to added T-toxin was consistent with the formation 
of a hydrophillic pore within the E. coli plasma mem- 
brane. Additional support for the relationship between 
URF13 expression and T-toxin sensitivity has been pro- 
vided by the expression of URF13 in the yeast Saccha- 
romyces cerevisiae [20,21], in insect cells using a bac- 
ulovirus-mediated xpression system [22] and in transgenic 
tobacco plants [23]. 
The expression of URF13 in E. coli has facilitated 
characterization f both URF13 protein structural features 
and the nature of its interaction with T-toxins. This paper 
presents an overview of recent studies that characterize the 
topological orientation of URF13 in the membrane, the 
interaction between URF13 and T-toxin, including amino 
acid residues involved, and the nature and role of oligomers 
in the interaction between URF13 and T-toxin. In addition, 
a preliminary characterization of the three-dimensional 
structure of the URF13 tetramer in the membrane is pre- 
sented. 
2. Materials and methods 
The expression of URF13 in E. coli was carried out as 
described previously [19,24,25]. Characterization of the 
topological orientation of URF13 within the membrane 
was done according to Korth et al. [24] using an URF13 
fusion protein having an eleven-amino acid sequence fused 
to the amino terminus of standard URFI3. Binding of 
tritiated, reduced P. maydis toxin (Pm toxin) to URF13 
expressed in E. coli was carried out using the procedure 
described by Braun et al. [26] involving the incubation of 
E. coli cells with variable concentrations of labeled Pm 
toxin followed by centrifugation through silicon oil to 
separate the bound and unbound toxin fractions. Site-di- 
rected [19,25] and doped oligonucleotide-directed [27] mu- 
tagenesis were performed as described previously. Chemi- 
cal cross-linking of URF13 oligomers using ethylene gly- 
col bis(succinimidylsuccinate) (EGS) and dicyclohexyl- 
carbodiimide (DCCD) was as described by Korth et al. 
[24] and Kaspi and Siedow [28], respectively. SDS-PAGE 
was carried out using gels containing 18% acrylamide [ 19]. 
Immunoblotting using anti-URF13 and anti-sl0 antibodies 
was carried out using previously described procedures 
[19,24,25,28]. 
3. Results and discussion 
3.1. URF13 membrane topology 
A common paradigm for the formation of hydrophillic 
pores by membrane proteins postulates a 'barrel-stave' 
structure in which there is the cylindrical association of 
several amphipathic membrane-spanning regions in the 
pore-forming protein such that the hydrophillic faces of the 
amphipathic regions line the pore and the hydrophobic 
faces are exposed to the hydrocarbon phase of the bilayer 
[29,30]. These considerations were coupled with the results 
of earlier mutagenesis studies to develop a model for the 
structure of URF13 [2,4] that envisioned a three-mem- 
brane-spanning a-helical arrangement (Fig. 1). A hydro- 
phobicity plot of the URF13 primary amino acid sequence 
indicates the potential for a hydrophobic membrane-span- 
ning region (helix I) between residues 10 and 30 [2]. Based 
upon hydrophobic moment calculations and helical wheel 
plots, two additional membrane-spanning, amphipathic a- 
helices can be postulated between residues 35 and 55 
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Fig. 1. Proposed model for the topological organization of URF13 in 
mitochondrial and bacterial membranes. Horizontal lines indicate the 
boundaries of the membrane. Asp-39, Lys-32, and Lys-37 are outlined in 
bold diamonds. The topology of the membrane is designated as being 
either the n- (electrochemically negative) or p- (electrochemically posi- 
tive) side of the membrane. 
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(helix II) and residues 61 and 83 (helix Ill), respectively 
[2]. Given their amphipathic nature, helices II and III are 
capable of lining the hydrophillic pore formed by URF13. 
To test the validity of the model shown in Fig. 1, direct 
localization of the amino and carboxy termini of URFI3 
was undertaken by constructing an URFI3 fusion protein 
that contained a 14-amino acid extension on the amino 
terminus of native URF13 [24]. This sequence was derived 
from the phage T7 sl0 coat protein and contained an 
l 1-amino acid sequence for which an antibody was com- 
mercially available. Because an antibody to a 15-amino 
acid region in the carboxy terminus of URF13 already 
existed [13], the resulting sI0:URF13 fusion protein con- 
tained antigenic tags at both ends of the molecule. Studies 
were carried out to determine the protease accessibility of 
the amino and carboxy termini of the fusion protein in E. 
coli membrane preparations having either ight-side-out or 
inside-out orientations [24]. The amino and carboxy ends 
of URFI3 were localized on opposite sides of the mem- 
brane, indicating that URF13 exists in the E. coli mem- 
brane with an odd number of membrane-spanning re ions. 
The size of the resulting proteolytic products was consis- 
tent with the three-helical model it was too large to have 
been derived from a protein having only a single mem- 
brane-spanning region and too small to have five mem- 
brane-spanning regions [24]. These results established the 
three-helical structure (Fig. 1) as the paradigm for subse- 
quent structural studies of URF13. 
3.2. URF13-T-toxin interactions 
A reasonable model for the mechanism of action of 
T-toxin involves its binding directly to URF13 and bring- 
ing about a conformational change in the URFI3 protein 
that produces a hydrophillic pore within the membrane. 
Tritiated, reduced T-toxin from P. maydis (Pm toxin) was 
observed to bind specifically to E. coli cells expressing 
URF13 in a cooperative manner [26]. Specific binding of 
Pm toxin to cms-T mitochondria was also observed [26]. 
The total amount of Pm toxin bound to E. coli cells was 
250 to 450 pmol per mg of total E. coli protein. The K d 
was 50 to 90 nM, in agreement with the concentration of
T-toxin needed to observe permeabilization i isolated 
cms-T mitochondria [ 10] or E. coli cells expressing URF13 
[18]. The Hill coefficient for the observed cooperativity 
ranged from 1.5 to 1.7 [26]. 
The ability to express a T-toxin responsive URF13 in 
E. coli cells provided the opportunity to carry out mutage- 
nesis studies to characterize specific functional domains 
within the URFI3 protein. Initially, three categories of 
toxin-resistant mutations were identified: (1) URFI3 
species truncated prior to amino acid 83 [19]; (2) mutations 
at Asp-39, changing this residue to any other amino acid 
resulted in a toxin-resistant protein [19]; and (3) a deletion 
mutation removing ten-amino acids near the URF13 amino 
terminus [ 18]. 
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Fig. 2. Location of methomyl-resistant mutation of URF13 within the 
proposed three-helix model. Residues outlined in bold diamonds indicate 
positions where an amino acid substitution resulted in a phenotype that is 
capable of growing in the presence of 8.0 mM methomyl. Adapted from 
[271. 
To characterize additional functional domains within 
the URF13 structure, doped oligonucleotide-directed muta- 
genesis was carried out on URF13 expressed in E. coli 
and mutations were selected for their ability to grow on a 
medium containing 8.0 mM methomyl [27]. This proce- 
dure resulted in the isolation of 73 separate substitutions 
located at 39 different amino acid positions within URF13, 
each of which conferred resistance to 8.0 mM methomyl 
(Fig. 2). Methomyl-resistant mutations were found within 
all three postulated membrane-spanning helices as well as 
the two interhelical regions and were uniformly distributed 
between residues 11 and 83 in the URFI3 primary se- 
quence (Fig. 2), the region constituting the complete 
URFI3 functional domain [19]. Mutations included substi- 
tutions of neutral for charged amino acids and vice versa, 
as well as many alterations that changed the standard 
amino acid to a proline residue. Interestingly, the 
methomyl-resistant proline substitutions were located ex- 
clusively in helices I and II. Apparently none of the 
potential proline substitutions that could have appeared in 
helix III produced a methomyl-resistant phenotype [27]. 
Every methomyl-resistant URF13 mutation was ob- 
served to form oligomers, as ascertained by chemical 
cross-linking using EGS (c.f., below). Many of the muta- 
tions showed levels of T-toxin binding significantly below 
that seen with standard URF13, suggesting some impair- 
ment of the T-toxin/methomyl binding site. These bind- 
ing-deficient mutations were localized throughout he 
URF13 primary sequence. A second category of mutations 
was characterized that showed sensitivity to methomyl 
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when treated with concentrations above 8.0 mM. These 
'methomyl-remedial' mutations were obtained at eight dif- 
ferent amino acid positions distributed among all three 
membrane-spanning re ions. These mutations were all re- 
stricted to the hydrophillic faces of helices II and III and 
hydrophillic residues in helix I. It appears that in the 
methomyl remedial mutations, URF13 retains an intrinsic 
sensitivity to methomyl (and T-toxin), but the affinity of 
the receptor for its ligand (i.e., K d) has been decreased. 
Finally, three methomyl-resistant mutations howed levels 
of T-toxin binding similar to that of standard URF13, but 
remained insensitive to methomyl and T-toxin, even at 
elevated levels. These mutations may be defective in pore 
formation. 
3.3. URF13 structural features 
Because NAD ÷ (M r = 663) can pass through the pores 
generated by URF13 [6], a pore diameter of 0.8-1.5 nm is 
indicated [31]. With a pore diameter of 1.0 nm, eight 
amphipathic helices would be needed to form the channel 
lining [31,32]. Using the three-helix model (Fig. 1), pore 
formation requires the association of URFI3 monomers 
into at least a tetrameric structure to accommodate he 
largest observed pores, assuming that amphipathic helices 
II and III both line the pore. The possibility that URF13 
exists as an oligomer was first suggested by the appear- 
ance of cooperativity in the binding of Pm toxin to URF13 
in E. coli [26] and by the appearance of URF13 dimeric 
species on SDS gels [33]. Covalent cross-linking studies 
using the lysine-specific homobifunctional cross-linking 
reagent EGS confirmed directly that a fraction of the 
URF13 exists in an oligomeric state, with dimers, trimers 
and some tetramers evident after EGS cross-linking [24]. 
Additional insights into the oligomeric nature of URF 13 
were provided by studies of the effect of the carboxylate- 
specific reagent DCCD on URF13. Previous work had 
demonstrated that addition of DCCD to isolated cms-T 
mitochondria led to a loss of sensitivity to T-toxin [34,35]; 
similar results were also obtained after DCCD treatment of 
E. coli cells expressing URF13 [19]. It was also observed 
that [InC]DCCD could covalently label URF13, and site- 
directed mutagenesis was used to establish that the site of 
DCCD labeling was Asp-39 [19]. More recently, DCCD 
has been shown to covalently cross-link URF13, revealing 
more higher-order (trimer and tetramer) species than with 
EGS cross-linking [28]. 
To understand the effects of DCCD on URF13, it is 
important to recognize that DCCD initially reacts specifi- 
cally with carboxylate residues to form an activated, 
DCCD-carboxylate intermediate that can either: (1) be 
hydrolyzed to an unmodified carboxylate with the loss of 
N, N'-dicyclohexylurea, (2)undergo rearrangement to form 
a covalently bonded DCCD adduct, or (3) react with a 
suitably positioned nucleophile, displacing the DCCD as a 
dialkylurea nd forming a covalent linkage between the 
nucleophile and the carboxylate residue [36,37]. The sec- 
ond reaction is slow relative to hydrolysis, so rearrange- 
ment to form a stable DCCD adduct occurs primarily with 
carboxylate r sidues localized in hydrophobic environ- 
ments [36]. With respect to the third reaction, epsilon 
amino groups on lysines represent the kinetically most 
active displacing nucleophile found in proteins [37], lead- 
ing to formation of an amide bond between the lysine and 
the DCCD-reactive carboxylate residue. If the displacing 
lysine is on a separate URFI 3 monomer from that of the 
activated DCCD-carboxytate intermediate, intermolecular 
cross-linking results. Because lysine displaces DCCD from 
the activated carboxylate by way of an S N 2-type reaction 
mechanism [36,37], the epsilon amino group must be 
closely positioned to the activated carboxylate residue 
within the protein structure. DCCD can thus be thought of 
as a 'zero-length' cross-linker that leads to an amide bond 
having a length of about 1.5 A. 
Reconciling the observations that DCCD can both cova- 
lently label and cross-link URF13 came with the realiza- 
tion that the 14C-labeled DCCD adduct only appeared in 
monomeric URF13 species on SDS gels, whereas the 
cross-linked, multimeric URFI3 species never contained 
any covalently bound [14C]DCCD (i.e., DCCD was dis- 
placed as a result of the intermolecular c oss-linking reac- 
tion) [19,28]. Within URF13 oligomers, the intermolecular 
cross-linking reaction is apparently favored kinetically and 
only in monomeric URFI 3 is the lifetime of the activated 
DCCD:Asp-39 intermediate sufficiently long to permit re- 
arrangement to form the DCCD adduct. 
The observation that DCCD is capable of covalently 
cross-linking URF13 oligomers also suggests a mechanism 
by which DCCD treatment leads to T-toxin insensitivity in 
URF 13. DCCD cross-linking appears to lock the oligomeric 
URF13 complex into a closed conformation that is unable 
to change to the open, pore-forming conformation after 
binding T-toxin. The ability of DCCD to protect E. coli 
cells expressing URFI3 against he deleterious effects of 
T-toxin was used to investigate the nature of the cross-lin- 
ked species needed to achieve the loss of T-toxin (or 
methomyl) sensitivity in DCCD-treated spheroplasts [28]. 
Although correlative in nature, the time course of appear- 
ance of T-toxin insensitivity in URF13 after addition of 
DCCD corresponded with the appearance of cross-linked 
trimers and tetramers on immunoblots [28]. If URF13 
trimers result from incompletely cross-linked tetramers 
[25], these results point to URFI 3 tetramers as the species 
responsible for toxin-mediated membrane pore formation. 
The DCCD cross-linking of URF13 provided a useful 
starting point for investigating intermolecular helix-helix 
interactions. Asp-39 had already been identified as one of 
the two reaction partners in DCCD cross-linking [19], and 
the other is, almost certainly, a lysine residue that must be 
sufficiently close to Asp-39 to displace DCCD and form a 
stable amide linkage [36,37]. Of the five lysine residues in 
URFI 3, three are found within the postulated pore-forming 
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domain (i.e., residues 1-83 [19]) and, of these three, only 
two (Lys-32 and -37) would be predicted to be in the 
vicinity of Asp-39 on adjacent monomers (Fig. 1). Lys-32 
is located in the interhelical region between helices I and II 
whereas Lys-37 is located near the amino-terminal end of 
helix II. 
Site-directed mutagenesis was carried out to generate 
separate URF13 molecules in which the lysine at position 
32 was changed to an alanine (K32A-URF13) and Lys-37 
was changed to isoleucine (K37I-URFI3), respectively 
[25]. Both mutant URF13 species were found to be sensi- 
tive to methomyl and T-toxin. Treatment of K32A-URFI 3 
with DCCD resulted in the loss of methomyl sensitivity as 
well as cross-linking into higher-order oligomers, analo- 
gous to the results obtained with standard URF13 [25]. In 
contrast, K37I-URFI3 remained sensitive to methomyl 
after DCCD treatment and the level of cross-linking was 
greatly reduced, with only a limited amount of dimer, and 
no trimer or tetramer, formation. These results suggest that 
DCCD cross-linking of URFI 3 involves a specific reaction 
between Asp-39 on one URF13 monomer and Lys-37 on 
an adjacent monomer. 
The juxtaposition of Asp-39 and Lys-37 on adjacent 
URF13 monomers, as ascertained by the site-directed mu- 
tagenesis:DCCD cross-linking studies described above, 
provides additional support for the proposed three-helical 
topological model of URFI3 (Fig. 1). In addition, the 
ability of DCCD to cross-link URF13 into tetramers on 
SDS-gels implies that four helices II must be closely 
aligned within the URF13 tetrameric omplex. This is 
readily accommodated if the URF13 tetramer consists of a 
central core of four helices II forming a four-helical bundle 
(Fig. 3). A helical wheel plot of such an arrangement of
helices II indicates that Asp-39 and Lys-37 on adjacent 
helices align themselves in a manner that should facilitate 
cross-linking after activation of Asp-39 by DCCD (Fig. 
3A). A three-dimensional representation of this structure 
within the membrane is shown in Fig. 3B. 
DCCD reacts with the closed-pore conformation of 
URFI 3 and prevents its changing to the open-pore confor- 
mation after addition of T-toxin or methomyl. It is easy to 
envision in Fig. 3A how intermolecular cross-linking of 
helices II within the URFI3 central core would lock the 
four-helical bundle into a closed state. Pore formation may 
involve a conformational change in this structure that 
opens up the central core, possibly by the insertion of the 
second amphipathic helix, helix III, between adjacent he- 
lices II [25]. Given that DCCD cross-linking requires the 
two participating amino acid residues to be closely aligned, 
it was of interest to test for the ability of DCCD to 
cross-link URFI3 after addition of either T-toxin or 
methomyl. Preincubation with either methomyl or T-toxin 
led to a marked reduction in DCCD cross-linking of 
URF13 in E. coli spheroplasts [25]. This result is consis- 
tent with the idea that a large conformational change takes 
place in the URF13 tetramer after T-toxin (or methomyl) 
binding leading to the formation of a hydrophillic pore. 
This conformational change moves Asp-39 and Lys-37 on 
adjacent helices II sufficiently far apart to prevent dis- 
placement of DCCD from the activated DCCD:Asp-39 
intermediate by Lys-37. Alternatively, T-toxin and 
methomyl may simply be positioned between Asp-39 and 
Lys-37 after binding to URF13, leading to decreased 
cross-linking due to simple steric hindrance. 
The inhibitory effects of methomyl on DCCD cross-lin- 
king can be reversed by washing the spheroplasts before 
the addition of DCCD [25]. This result suggests that 
hydrophillic pore formation by URF13 is a reversible 
process that is effectively 'ligand gated.' Binding of the 
ligand (i.e., T-toxin or methomyl) to the T-toxin receptor 
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Fig. 3. Postulated central core of four helices II within the URFI3 tetramer. (A) Helical wheel projection of the four helix bundle viewed parallel to the 
plane of the membrane. Polar residues are circled, except for Asp-39 and Lys-37, which are outlined in bold diamonds. (B) Schematic three-dimensional 
representation f the helix II central core within the membrane. Each shaded cylinder epresents a single helix II. The positions of helices I and III relative 
to helix II are not known and should be taken as arbitrary within this figure. The topology of the membrane is designated as being either the n- 
(electrochemically negative) or p- (electrochemically positive) side of the membrane. Adapted from [25]. 
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(i.e., URF13) is required for pore formation and removal 
of the ligand from the receptor leads to pore closing. 
Although additional studies are needed to characterize 
further both the structure of URF13 and the nature of its 
interactions with T-toxin, the current understanding of the 
structure-function relationships associated with toxin/re- 
ceptor interactions in URF13 make this one of the best 
characterized receptors among higher plants. 
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